ALZECURE PHARMA (Germany) Performance
| AC6 Stock | EUR 0.19 0.01 5.00% |
On a scale of 0 to 100, ALZECURE PHARMA holds a performance score of 3. The firm shows a Beta (market volatility) of -0.47, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning ALZECURE PHARMA are expected to decrease at a much lower rate. During the bear market, ALZECURE PHARMA is likely to outperform the market. Please check ALZECURE PHARMA's value at risk, downside variance, and the relationship between the maximum drawdown and potential upside , to make a quick decision on whether ALZECURE PHARMA's price patterns will revert.
Risk-Adjusted Performance
Soft
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in ALZECURE PHARMA AB are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Despite nearly unsteady basic indicators, ALZECURE PHARMA reported solid returns over the last few months and may actually be approaching a breakup point. ...more
ALZECURE |
ALZECURE PHARMA Relative Risk vs. Return Landscape
If you would invest 22.00 in ALZECURE PHARMA AB on July 15, 2025 and sell it today you would lose (3.00) from holding ALZECURE PHARMA AB or give up 13.64% of portfolio value over 90 days. ALZECURE PHARMA AB is currently producing 0.5412% returns and takes up 12.7176% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than ALZECURE, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
ALZECURE PHARMA Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for ALZECURE PHARMA's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as ALZECURE PHARMA AB, and traders can use it to determine the average amount a ALZECURE PHARMA's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0426
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | AC6 | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 12.72 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.54 actual daily | 10 90% of assets have higher returns |
Risk-Adjusted Return
| 0.04 actual daily | 3 97% of assets perform better |
Based on monthly moving average ALZECURE PHARMA is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ALZECURE PHARMA by adding it to a well-diversified portfolio.
ALZECURE PHARMA Fundamentals Growth
ALZECURE Stock prices reflect investors' perceptions of the future prospects and financial health of ALZECURE PHARMA, and ALZECURE PHARMA fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ALZECURE Stock performance.
| Return On Equity | -1.55 | |||
| Return On Asset | -0.78 | |||
| Shares Outstanding | 59.19 M | |||
| Price To Earning | (183.73) X | |||
| EBITDA | 2.58 M | |||
| Cash And Equivalents | 18.67 M | |||
| Cash Per Share | 0.06 X | |||
| Total Debt | 723.85 K | |||
| Debt To Equity | 0.80 % | |||
| Book Value Per Share | 0.28 X | |||
| Cash Flow From Operations | 356.17 K | |||
About ALZECURE PHARMA Performance
By analyzing ALZECURE PHARMA's fundamental ratios, stakeholders can gain valuable insights into ALZECURE PHARMA's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if ALZECURE PHARMA has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if ALZECURE PHARMA has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
AlzeCure Pharma AB , a pharmaceutical company, develops drug therapies for the treatment of Alzheimers and Parkinsons diseases. The company was founded in 2012 and is based in Huddinge, Sweden. ALZECURE PHARMA operates under Drug Manufacturers - Specialty Generic classification in Germany and is traded on Frankfurt Stock Exchange. It employs 2 people.Things to note about ALZECURE PHARMA AB performance evaluation
Checking the ongoing alerts about ALZECURE PHARMA for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ALZECURE PHARMA AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ALZECURE PHARMA AB is way too risky over 90 days horizon | |
| ALZECURE PHARMA AB has some characteristics of a very speculative penny stock | |
| ALZECURE PHARMA AB appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (7.21 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| About 34.0% of the company shares are held by company insiders |
- Analyzing ALZECURE PHARMA's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ALZECURE PHARMA's stock is overvalued or undervalued compared to its peers.
- Examining ALZECURE PHARMA's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ALZECURE PHARMA's management team can have a significant impact on its success or failure. Reviewing the track record and experience of ALZECURE PHARMA's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ALZECURE PHARMA's stock. These opinions can provide insight into ALZECURE PHARMA's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for ALZECURE Stock analysis
When running ALZECURE PHARMA's price analysis, check to measure ALZECURE PHARMA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ALZECURE PHARMA is operating at the current time. Most of ALZECURE PHARMA's value examination focuses on studying past and present price action to predict the probability of ALZECURE PHARMA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ALZECURE PHARMA's price. Additionally, you may evaluate how the addition of ALZECURE PHARMA to your portfolios can decrease your overall portfolio volatility.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |